Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which… Read More
Today the Amyloidosis Research Consortium (ARC), a patient-led research organization for amyloidosis diseases, announces the launch of ASPIRE: Amyloidosis Stakeholder Partnerships for Impact Reach and Equity, a collaborative of biotech and… Read More
OTTAWA, ON – BioTalent Canada today announced that its recently launched I.D.E.A.L. Bioscience EmployerTM recognition program is now accepting applications. This new employer recognition program, which represents Inclusivity, Diversity, Equity, and… Read More
TALZENNA® first PARP inhibitor to demonstrate clinical benefit in combination with XTANDI® in metastatic castration-resistant prostate cancer (mCRPC) Study achieves primary endpoint of radiographic progression-free survival Robust, highly consistent efficacy demonstrated in… Read More
TORONTO, ON — Bloom Burton & Co. (“Bloom Burton”) is pleased to announce Pieter Cullis, Co-Founder of Acuitas Therapeutics, as the recipient of the 2022 Bloom Burton Award. Pieter Cullis… Read More
